|
GB0526211D0
(en)
*
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Viral vectors
|
|
WO2007091066A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Ucl Business Plc |
Applications of non-integrating lentiviral vectors
|
|
PL2020444T3
(pl)
*
|
2007-08-03 |
2017-10-31 |
Pasteur Institut |
Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek
|
|
MX2010001379A
(es)
|
2007-08-03 |
2010-06-08 |
Pasteur Institut |
Vectores de tranferencia de gen lentiviral y sus aplicaciones medicinales.
|
|
AU2013203404B2
(en)
*
|
2007-08-03 |
2016-10-13 |
Centre National De La Recherche Scientifique (Cnrs) |
Lentiviral gene transfer vectors and their medicinal applications
|
|
WO2009054985A1
(en)
|
2007-10-25 |
2009-04-30 |
Sangamo Biosciences, Inc. |
Methods and compositions for targeted integration
|
|
CN102046785A
(zh)
*
|
2008-03-28 |
2011-05-04 |
维克西斯公司 |
基于慢病毒的免疫原性载体
|
|
WO2009131706A1
(en)
*
|
2008-04-26 |
2009-10-29 |
Yung-Nien Chang |
Site-specific-integration lentiviral vectors
|
|
RU2012140691A
(ru)
*
|
2009-03-13 |
2014-03-27 |
Лентиген Корпорейшен |
Вакцины на основе неинтегрирующегося ретровирусного вектора
|
|
EP2419511B1
(en)
|
2009-04-09 |
2018-01-17 |
Sangamo Therapeutics, Inc. |
Targeted integration into stem cells
|
|
US8956828B2
(en)
|
2009-11-10 |
2015-02-17 |
Sangamo Biosciences, Inc. |
Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
|
|
WO2011100058A1
(en)
|
2010-02-09 |
2011-08-18 |
Sangamo Biosciences, Inc. |
Targeted genomic modification with partially single-stranded donor molecules
|
|
EP2385107B1
(en)
|
2010-05-03 |
2016-08-24 |
Institut Pasteur |
Lentiviral vector based immunological compounds against malaria
|
|
WO2012152912A1
(en)
|
2011-05-12 |
2012-11-15 |
Newvectys |
Genetically modified pig as a cancer prone model
|
|
ES2651922T3
(es)
|
2011-11-08 |
2018-01-30 |
Institut Pasteur |
Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
|
|
GB201202516D0
(en)
|
2012-02-13 |
2012-03-28 |
Ucl Business Plc |
Materials and methods relating to packaging cell lines
|
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
|
MX362699B
(es)
|
2012-03-30 |
2019-02-01 |
Immune Design Corp |
Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign.
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
JP2016501531A
(ja)
|
2012-12-12 |
2016-01-21 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作および治療適用のための系、方法および組成物の送達、エンジニアリングおよび最適化
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
JP6738729B2
(ja)
*
|
2013-06-17 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
分裂終了細胞の疾患および障害をターゲティングおよびモデリングするための系、方法および組成物の送達、エンジニアリングおよび最適化
|
|
JP6625971B2
(ja)
|
2013-06-17 |
2019-12-25 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
配列操作のためのタンデムガイド系、方法および組成物の送達、エンジニアリングおよび最適化
|
|
EP4245853A3
(en)
|
2013-06-17 |
2023-10-18 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
MX374532B
(es)
|
2013-06-17 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
KR20160030187A
(ko)
|
2013-06-17 |
2016-03-16 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도
|
|
WO2015040063A1
(en)
*
|
2013-09-17 |
2015-03-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Lentiviral vectors having a mutated integrase protein and uses thereof
|
|
EP2878667A1
(en)
|
2013-11-29 |
2015-06-03 |
Institut Pasteur |
TAL effector means useful for partial or full deletion of DNA tandem repeats
|
|
KR102805572B1
(ko)
|
2013-12-12 |
2025-05-09 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP4219699A1
(en)
|
2013-12-12 |
2023-08-02 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
EP3653703A1
(en)
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
BR112016013207A2
(pt)
|
2013-12-12 |
2017-09-26 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
PL3689899T3
(pl)
|
2014-04-25 |
2022-01-31 |
2Seventy Bio, Inc. |
Chimeryczne receptory antygenowe promotora mnd
|
|
ES2800906T3
(es)
|
2014-04-25 |
2021-01-05 |
Bluebird Bio Inc |
Métodos mejorados para producir terapias celulares adoptivas
|
|
SG10202108458XA
(en)
|
2014-06-06 |
2021-09-29 |
2Seventy Bio Inc |
Improved t cell compositions
|
|
KR102523934B1
(ko)
|
2014-07-24 |
2023-04-20 |
2세븐티 바이오, 인코포레이티드 |
Bcma 키메릭 항원 수용체
|
|
EP3031923A1
(en)
|
2014-12-11 |
2016-06-15 |
Institut Pasteur |
Lentiviral vector-based japanese encephalitis immunogenic composition
|
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094304A2
(en)
|
2014-12-12 |
2016-06-16 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
SG10201912329YA
(en)
|
2015-06-18 |
2020-02-27 |
Broad Inst Inc |
Crispr Enzyme Mutations Reducing Off-Target Effects
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
US10701165B2
(en)
|
2015-09-23 |
2020-06-30 |
Sensoriant, Inc. |
Method and system for using device states and user preferences to create user-friendly environments
|
|
WO2017060662A1
(en)
*
|
2015-10-07 |
2017-04-13 |
The Secretary Of State For Health |
Method for providing a control for use in a screen for pathogenic virus
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
CN109311963A
(zh)
|
2016-04-14 |
2019-02-05 |
蓝鸟生物公司 |
救助嵌合抗原受体系统
|
|
WO2017214938A1
(zh)
*
|
2016-06-16 |
2017-12-21 |
毛侃琅 |
特异促进 bace1 基因高表达的慢病毒表达载体及应用
|
|
EP3500696A4
(en)
|
2016-08-16 |
2020-04-08 |
Bluebird Bio, Inc. |
VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE
|
|
CA3034782A1
(en)
|
2016-08-23 |
2018-03-01 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
ES2952525T3
(es)
|
2016-09-08 |
2023-11-02 |
2Seventy Bio Inc |
Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
|
|
JP7060591B2
(ja)
|
2016-10-17 |
2022-04-26 |
２セブンティ バイオ インコーポレイテッド |
ＴＧＦβＲ２エンドヌクレアーゼバリアント、組成物、および使用方法
|
|
MA46723A
(fr)
|
2016-11-04 |
2019-09-11 |
Bluebird Bio Inc |
Compositions de lymphocytes t car anti-bcma
|
|
MX2019005724A
(es)
|
2016-11-17 |
2019-07-08 |
Bluebird Bio Inc |
Conversor de se?ales de tgfbeta.
|
|
KR20190089988A
(ko)
*
|
2016-12-06 |
2019-07-31 |
블루버드 바이오, 인코포레이티드. |
I형 점액다당류증에 대한 유전자 요법
|
|
CA3046080A1
(en)
*
|
2016-12-06 |
2018-06-14 |
Bluebird Bio, Inc. |
Gene therapy for mucopolysaccharidosis, type ii
|
|
EP3357506A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
|
|
EP3357504A1
(en)
|
2017-02-02 |
2018-08-08 |
Institut Pasteur |
Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
|
|
AU2018221730B2
(en)
|
2017-02-15 |
2024-06-20 |
Novo Nordisk A/S |
Donor repair templates multiplex genome editing
|
|
JP7191042B2
(ja)
|
2017-05-25 |
2022-12-16 |
２セブンティ バイオ インコーポレイテッド |
Ｃｂｌｂエンドヌクレアーゼバリアント、組成物、および使用方法
|
|
US11779654B2
(en)
|
2017-10-04 |
2023-10-10 |
2Seventy Bio, Inc. |
PCSK9 endonuclease variants, compositions, and methods of use
|
|
EP3502260A1
(en)
|
2017-12-22 |
2019-06-26 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
DE102018100967B4
(de)
|
2018-01-17 |
2019-08-14 |
Immatics US, Inc. |
Verfahren zur feststellung der wirksamkeit von viralen vektoren
|
|
DE102018010282A1
(de)
|
2018-01-17 |
2019-07-18 |
Immatics US, Inc. |
Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
|
|
KR102887853B1
(ko)
|
2018-06-14 |
2025-11-19 |
리제너론 파마슈티칼스 인코포레이티드 |
Cd79a 키메라 항원 수용체
|
|
CN112689516A
(zh)
|
2018-07-11 |
2021-04-20 |
细胞基因公司 |
抗bcma嵌合抗原受体的用途
|
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
|
WO2020072059A1
(en)
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
AU2019397364B8
(en)
|
2018-12-10 |
2025-08-07 |
Novo Nordisk A/S |
Homing endonuclease variants
|
|
KR20210104772A
(ko)
|
2018-12-14 |
2021-08-25 |
블루버드 바이오, 인코포레이티드. |
이량체화제로 조절된 면역수용체 복합체
|
|
WO2020205889A1
(en)
|
2019-04-01 |
2020-10-08 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2021007515A1
(en)
|
2019-07-11 |
2021-01-14 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
EP3770264A1
(en)
|
2019-07-22 |
2021-01-27 |
Genethon |
Precise integration using nuclease targeted idlv
|
|
CN114401989B
(zh)
|
2019-09-20 |
2024-02-09 |
上海吉倍生物技术有限公司 |
靶向bcma的抗体及嵌合抗原受体
|
|
JP2022554351A
(ja)
|
2019-11-05 |
2022-12-28 |
セルジーン コーポレイション |
抗ｂｃｍａキメラ抗原受容体の使用法
|
|
KR20220097492A
(ko)
|
2019-11-12 |
2022-07-07 |
옥스포드 바이오메디카(유케이) 리미티드 |
생산 시스템
|
|
EP4103723A1
(en)
|
2020-02-13 |
2022-12-21 |
Oxford BioMedica (UK) Limited |
Production of lentiviral vectors
|
|
CN115667534A
(zh)
|
2020-03-13 |
2023-01-31 |
牛津生物医学（英国）有限公司 |
慢病毒载体
|
|
WO2021212279A1
(zh)
*
|
2020-04-20 |
2021-10-28 |
广东东阳光药业有限公司 |
慢病毒的滴度提高型转移质粒
|
|
CN114807228B
(zh)
*
|
2020-04-27 |
2023-12-15 |
北京化工大学 |
一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
EP3984548A1
(en)
|
2020-10-16 |
2022-04-20 |
Institut Pasteur |
Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
|
|
KR20230113755A
(ko)
|
2020-11-04 |
2023-08-01 |
셀진 코포레이션 |
선행 항암 알킬화제 요법을 받은 환자에서의 car t 세포 요법
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
EP4272002A1
(en)
|
2020-12-04 |
2023-11-08 |
Celgene Corporation |
Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
|
|
AU2022233021A1
(en)
|
2021-03-12 |
2023-09-21 |
Institut Pasteur |
Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
|
|
CA3214280A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
T cell therapy in patients who have had prior stem cell transplant
|
|
KR20240034234A
(ko)
|
2021-07-14 |
2024-03-13 |
2세븐티 바이오, 인코포레이티드 |
항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
CN114181972A
(zh)
*
|
2021-11-23 |
2022-03-15 |
上海本导基因技术有限公司 |
适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
IL316032A
(en)
|
2022-04-08 |
2024-11-01 |
Regeneron Pharma |
Multicomponent receptor and signaling complexes
|
|
CA3246384A1
(en)
|
2022-04-13 |
2023-10-19 |
Fundació Hospital Universitari Vall D'hebron - Institut De Recerca |
TREATMENT OF NEUROMUSCULAR DISEASES BY GENE THERAPY EXPRESSING THE KLOTHO PROTEIN
|
|
JP2025516629A
(ja)
|
2022-05-11 |
2025-05-30 |
セルジーン コーポレーション |
Ｔ細胞療法に関連する方法および使用、ならびにその生成
|
|
IL317172A
(en)
|
2022-05-26 |
2025-01-01 |
Regeneron Pharma |
Lentiviral vector maintenance vehicles and uses thereof
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
CN120202017A
(zh)
|
2022-10-21 |
2025-06-24 |
赛拉福柯蒂斯公司 |
表达选自denv、zikv及yfv的黄病毒的非结构抗原、诱导宿主中保护性cd8+t细胞免疫的多核苷酸及慢病毒载体
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
WO2024200573A1
(en)
|
2023-03-27 |
2024-10-03 |
LAVA Therapeutics N.V. |
Nectin-4 binding agents and methods of use
|
|
WO2025012118A2
(en)
|
2023-07-07 |
2025-01-16 |
LAVA Therapeutics N.V. |
5t4 binding agents and methods of use
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025153530A1
(en)
|
2024-01-16 |
2025-07-24 |
Novo Nordisk A/S |
Albumin-targeted endonucleases, compositions, and methods of use
|
|
WO2025235862A1
(en)
|
2024-05-10 |
2025-11-13 |
Inndura Therapeutics Inc. |
A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a
|